GO:0032689 negative regulation of type II interferon production: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032689 describes any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-gamma (type II interferon) production.
• Interferon-gamma is a critical cytokine for macrophage activation, antigen presentation, and Th1 immunity, so its negative regulation is essential to prevent immunopathology.
• Key negative regulators include cytokines (IL-4, IL-10, TGF-beta), transcription factors (ATF3, AIRE), and signaling molecules (SH2B3/LNK, OX40/OX40L).
• Dysregulation of this process contributes to autoimmunity, chronic infection, and cancer immune evasion.
• Post-transcriptional control, including mRNA stability and microRNAs, is a major layer of negative regulation of interferon-gamma production.
• CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of specific genes in this pathway.
Description
Interferon-gamma (IFN-gamma), also known as type II interferon, is a pleiotropic cytokine that is central to both innate and adaptive immunity. It is produced primarily by activated T lymphocytes and natural killer (NK) cells and is essential for macrophage activation, upregulation of MHC molecules, and defense against intracellular pathogens. Because excessive or prolonged IFN-gamma production can cause tissue damage and autoimmune pathology, its production is tightly controlled by multiple negative regulatory mechanisms. The Gene Ontology term GO:0032689, negative regulation of type II interferon production, captures any process that stops, prevents, or reduces the frequency, rate, or extent of IFN-gamma production. This term encompasses transcriptional, post-transcriptional, and signaling events that dampen IFN-gamma synthesis or secretion. Understanding these mechanisms is critical for developing therapies for inflammatory diseases, autoimmunity, and cancer. This article provides a research-grade overview of GO:0032689, integrating authoritative QuickGO annotation data with real PubMed literature to support experimental design and CRISPR-based modeling.
negative regulation of type II interferon production At A Glance
| GO ID | GO:0032689 |
|---|---|
| GO term | negative regulation of type II interferon production |
| Ontology | biological_process |
| Synonym | down regulation of interferon-gamma production; down-regulation of interferon-gamma production; downregulation of interferon-gamma production; inhibition of interferon-gamma production; negative regulation of interferon-gamma biosynthetic process; negative regulation of interferon-gamma production; negative regulation of interferon-gamma secretion |
| Major function | Dampening or preventing the production of interferon-gamma (type II interferon) to avoid excessive immune activation and tissue damage. |
| Related processes | Regulation of cytokine production, T cell activation, NK cell activation, macrophage activation, immune tolerance. |
| Cellular context | Occurs in immune cells such as T helper 1 (Th1) cells, CD8+ T cells, NK cells, and antigen-presenting cells. |
| Disease relevance | Autoimmunity, chronic inflammatory diseases, cancer immune evasion, and susceptibility to intracellular infections. |
What Is GO:0032689?
GO:0032689 (negative regulation of type II interferon production) is a biological process defined as any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon. This term includes negative regulation of interferon-gamma biosynthetic process and negative regulation of interferon-gamma secretion, and it is synonymous with down regulation, down-regulation, downregulation, or inhibition of interferon-gamma production.
Why Is negative regulation of type II interferon production Important in Cell Biology?
Negative regulation of type II interferon production is essential for maintaining immune homeostasis. IFN-gamma is a potent pro-inflammatory cytokine; without negative regulation, sustained IFN-gamma production can lead to chronic inflammation, tissue destruction, and autoimmune diseases such as type 1 diabetes and multiple sclerosis. Conversely, insufficient negative regulation can impair pathogen clearance. Understanding the molecular players that negatively regulate IFN-gamma production provides targets for therapeutic intervention in autoimmune diseases, chronic infections, and cancer immunotherapy.
• Prevents immunopathology by limiting excessive IFN-gamma during acute and chronic infections.
• Maintains peripheral tolerance and prevents autoimmunity.
• Modulates antitumor immunity; negative regulators can promote tumor immune evasion.
• Influences the balance between Th1 and Th2 immune responses.
• Affects macrophage polarization and inflammatory mediator production.
• Is a key mechanism of action for immunosuppressive cytokines such as IL-10 and TGF-beta.
• Dysregulation is linked to susceptibility to intracellular pathogens like Mycobacterium tuberculosis.
• Provides biomarkers and therapeutic targets for inflammatory and autoimmune diseases.
• Critical for successful organ transplantation by controlling graft rejection.
• Involved in neuroinflammation and neurodegenerative disease progression.
What Happens During negative regulation of type II interferon production?
Initiation of negative regulatory signals
In simple terms: The process begins when a cell receives signals that tell it to stop making interferon-gamma.
Negative regulation of type II interferon production is initiated by extracellular cues such as anti-inflammatory cytokines (e.g., IL-4, IL-10, TGF-beta), engagement of inhibitory receptors (e.g., OX40/OX40L interaction), or intracellular stress signals. These signals activate specific transcription factors and signaling cascades that ultimately suppress IFN-gamma gene expression. For example, OX40/OX40L interaction has been shown to negatively regulate IL-17 production, and similar mechanisms may apply to IFN-gamma. Additionally, asbestos exposure can induce IL-17 production from human CD4+ cells, suggesting that environmental factors can modulate cytokine production.
Transcriptional repression of IFNG
In simple terms: Inside the nucleus, specific proteins bind to the interferon-gamma gene and turn it off.
Transcriptional repression of the IFNG gene is a major mechanism. The transcription factor ATF3 has been implicated in the negative regulation of iNOS expression and NO production in activated macrophages, and it may similarly repress IFNG transcription. AIRE (autoimmune regulator) is known to regulate negative selection in the thymus and can influence the production of cytokines including IFN-gamma. The SH2B3/LNK adaptor protein has been shown to modulate hypertension and renal damage, and it may also affect cytokine signaling. These factors act by recruiting co-repressors or competing with activators at the IFNG promoter.
Post-transcriptional control of IFN-gamma mRNA
In simple terms: Even if the gene is turned on, the mRNA can be destroyed or prevented from making protein.
Post-transcriptional mechanisms, including mRNA stability and microRNA-mediated degradation, play a critical role in controlling IFN-gamma production. Khabar et al. (2007) reviewed post-transcriptional control of the interferon system, highlighting that AU-rich elements in the 3' untranslated region of IFN-gamma mRNA can be targeted by RNA-binding proteins and microRNAs to reduce mRNA half-life and translation. This layer of regulation allows rapid dampening of IFN-gamma production without new transcription.
Inhibition of IFN-gamma secretion
In simple terms: The cell may still make interferon-gamma but block its release outside.
Negative regulation can also occur at the level of secretion. IFN-gamma is secreted via the classical ER-Golgi pathway, and its release can be inhibited by proteins that interfere with vesicle trafficking or by signals that retain IFN-gamma intracellularly. While specific inhibitors of IFN-gamma secretion are less well characterized, the GO term includes negative regulation of interferon-gamma secretion. This may involve modulation of SNARE proteins or other trafficking machinery, as suggested by general studies on cytokine secretion.
Feedback inhibition by IFN-gamma signaling
In simple terms: Interferon-gamma itself can trigger signals that eventually shut down its own production.
IFN-gamma activates the JAK-STAT signaling pathway, which induces the expression of suppressor of cytokine signaling (SOCS) proteins and other negative feedback regulators. Platanias et al. (1999) described signaling pathways activated by interferons, including the induction of negative regulators that can attenuate IFN-gamma production. This feedback loop prevents runaway immune activation and is essential for resolving inflammation.
Key Genes Involved in GO:0032689 negative regulation of type II interferon production
The following genes and proteins have been experimentally implicated in the negative regulation of type II interferon production, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AIRE | Transcription factor regulating immune tolerance and cytokine production | Mutations cause autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED); studied in thymic negative selection |
| SH2B3 (LNK) | Adaptor protein modulating cytokine signaling and hypertension | Single nucleotide polymorphism linked to hypertension and renal damage; may affect IFN-gamma production |
| OX40L (TNFSF4) | Costimulatory molecule that can negatively regulate IL-17 production | Potential role in T cell cytokine regulation; studied in autoimmunity |
| ATF3 | Stress-inducible transcription factor | Negatively regulates iNOS and NO production in macrophages; may repress IFNG |
| IL-10 | Anti-inflammatory cytokine | Suppresses IFN-gamma production by T cells and NK cells; key negative regulator |
| TGF-beta | Immunosuppressive cytokine | Inhibits IFN-gamma production and Th1 differentiation |
| IL-4 | Th2 cytokine | Antagonizes Th1 development and IFN-gamma production |
| SOCS1 | Suppressor of cytokine signaling | Feedback inhibitor of IFN-gamma signaling and production |
| SOCS3 | Suppressor of cytokine signaling | Attenuates IFN-gamma-induced STAT1 activation |
| STAT1 | Transcription factor mediating IFN-gamma responses | Can induce negative feedback regulators |
| JAK1/2 | Janus kinases | Mediate IFN-gamma signaling and feedback inhibition |
| LRRK2 | Leucine-rich repeat kinase 2 | Interacts with IFN-gamma signaling in neurons and microglia |
| miR-29 | MicroRNA | Post-transcriptional regulator of IFN-gamma mRNA stability |
| HuR (ELAVL1) | RNA-binding protein | Stabilizes AU-rich element-containing mRNAs including IFN-gamma |
| TTP (ZFP36) | RNA-binding protein | Destabilizes IFN-gamma mRNA via AU-rich elements |
| NF-kB | Transcription factor | Can both activate and repress IFNG depending on context |
| T-bet (TBX21) | Transcription factor | Master regulator of Th1 and IFN-gamma; its negative regulation is critical |
| GATA3 | Transcription factor | Th2 master regulator that suppresses Th1 and IFN-gamma production |
How Is negative regulation of type II interferon production Regulated?
Negative regulation of type II interferon production is controlled by multiple layers of regulation. At the transcriptional level, factors such as ATF3, AIRE, and GATA3 can repress IFNG expression. Post-transcriptionally, RNA-binding proteins like TTP and HuR, as well as microRNAs such as miR-29, control IFN-gamma mRNA stability and translation. Signaling pathways, including JAK-STAT and SOCS-mediated feedback, provide rapid inhibition. Additionally, costimulatory molecules like OX40/OX40L can modulate cytokine production. Environmental factors such as asbestos exposure may also influence cytokine production. The interplay between these mechanisms ensures that IFN-gamma production is tightly controlled to prevent immunopathology.
negative regulation of type II interferon production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AIRE | Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) | AIRE knockout mice or human iPSC-derived thymic epithelial cells |
| SH2B3 (LNK) | Hypertension and renal damage | SH2B3 knockout rats or CRISPR knock-in of the risk SNP |
| LRRK2 | Parkinson's disease and neuroinflammation | LRRK2 G2019S knock-in iPSC-derived neurons and microglia |
| IL-10 | Inflammatory bowel disease and autoimmunity | IL-10 knockout mice or overexpression in T cells |
| TGF-beta | Cancer immune evasion and fibrosis | TGF-beta receptor knockout T cells or overexpression models |
Autoimmune diseases
Defective negative regulation of IFN-gamma production can lead to autoimmunity. For example, mutations in AIRE cause APECED, an autoimmune disease characterized by multiple endocrine deficiencies, due to impaired thymic negative selection and dysregulated cytokine production. Similarly, polymorphisms in SH2B3/LNK have been associated with hypertension and renal damage, which may involve altered cytokine signaling. Excessive IFN-gamma is a hallmark of several autoimmune conditions, including type 1 diabetes and multiple sclerosis.
Chronic infections
In chronic infections such as tuberculosis, prolonged IFN-gamma production can cause tissue damage, while insufficient negative regulation may fail to control pathogen growth. The balance is critical. Post-transcriptional control of IFN-gamma mRNA by RNA-binding proteins and microRNAs is important for resolving inflammation without compromising host defense.
Cancer immune evasion
Tumors can exploit negative regulatory pathways to suppress IFN-gamma production by T cells and NK cells, thereby evading immune destruction. For example, tumor-derived TGF-beta and IL-10 inhibit IFN-gamma production. Understanding these mechanisms is essential for developing cancer immunotherapies.
Neuroinflammation and neurodegeneration
IFN-gamma signaling in the central nervous system can contribute to neuroinflammation. LRRK2, a gene associated with Parkinson's disease, synergizes with IFN-gamma signaling in neurons and microglia derived from human induced pluripotent stem cells, suggesting that negative regulation of IFN-gamma production may be relevant to neurodegenerative diseases.
From negative regulation of type II interferon production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate IFN-gamma production? | CRISPR knockout of gene X in primary T cells or Jurkat cells, followed by IFN-gamma ELISA |
| Does a specific point mutation in gene X affect its function? | CRISPR point mutation (e.g., base editing) to introduce the variant, then measure IFN-gamma |
| Does overexpression of gene X suppress IFN-gamma? | Lentiviral overexpression of gene X in T cells, then measure IFN-gamma |
| Does gene X interact with IFN-gamma promoter? | CRISPR knock-in of a tagged version of gene X (e.g., HA-tag) followed by ChIP-seq |
| What is the role of gene X in vivo? | CRISPR knockout mouse models or humanized mice |
| Can we identify novel negative regulators? | Genome-wide CRISPR library screening with IFN-gamma reporter |
How to Study the negative regulation of type II interferon production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on IFN-gamma production | Identify novel negative regulators |
| RNA-seq | Transcriptome changes including IFNG mRNA | Assess transcriptional regulation |
| RIP-seq | RNA-protein interactions | Map binding of HuR, TTP to IFN-gamma mRNA |
| ELISA | Secreted IFN-gamma protein | Quantify cytokine production |
| Flow cytometry | Intracellular IFN-gamma | Single-cell analysis of T cells and NK cells |
| Western blot | Protein expression of regulators | Validate knockout or overexpression |
| ChIP-seq | Transcription factor binding to IFNG locus | Identify repressors like ATF3 |
| CRISPR base editing | Specific point mutations | Study disease-associated variants |
CRISPR knockout screening
Genome-wide CRISPR knockout screens can identify genes whose loss increases IFN-gamma production, revealing negative regulators. This approach uses a reporter cell line (e.g., IFN-gamma promoter-driven GFP) and next-generation sequencing to quantify sgRNA enrichment.
RNA-seq and transcriptomics
RNA sequencing can measure changes in IFNG mRNA levels and identify co-regulated genes upon perturbation of candidate negative regulators. This provides a global view of transcriptional networks.
Proteomics and immunoprecipitation
Mass spectrometry-based proteomics can identify proteins that interact with IFN-gamma mRNA or its regulatory regions. Immunoprecipitation of RNA-binding proteins followed by sequencing (RIP-seq) can map binding sites.
Flow cytometry and ELISA
Intracellular cytokine staining and ELISA are standard methods to quantify IFN-gamma protein production at the single-cell and population levels, respectively. These are essential for validating CRISPR perturbations.
How CRISPR Can Be Used to Study GO:0032689 negative regulation of type II interferon production
Knockout
CRISPR knockout is used to delete candidate negative regulator genes (e.g., ATF3, SOCS1) in immune cells. Loss of function typically leads to increased IFN-gamma production, confirming a negative regulatory role. This approach is high-throughput and can be scaled to genome-wide screens.
Point Mutation
CRISPR base editing or prime editing can introduce specific point mutations (e.g., SNPs in SH2B3) to study their impact on IFN-gamma regulation. This is particularly useful for modeling human genetic variants associated with autoimmune or inflammatory diseases.
Knock-in
Knock-in of tagged versions of regulatory proteins (e.g., HA-ATF3) allows for chromatin immunoprecipitation and imaging studies to determine their localization and interactions at the IFNG locus. Knock-in of reporter genes (e.g., GFP) can also be used to track IFN-gamma expression in real time.
Overexpression
Overexpression of candidate negative regulators (e.g., IL-10, TGF-beta) using lentiviral vectors can suppress IFN-gamma production, providing gain-of-function evidence. This is useful for validating therapeutic targets.
How EDITGENE Supports negative regulation of type II interferon production Research
Researchers studying negative regulation of type II interferon production-related genes often need to determine whether a candidate gene is causally involved in suppressing IFN-gamma production. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic perturbations in immune cells and model systems.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of type II interferon production research.
Frequently Asked Questions About negative regulation of type II interferon production
What is GO:0032689?
GO:0032689 is a Gene Ontology term for negative regulation of type II interferon production, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-gamma production.
What genes are involved in negative regulation of type II interferon production?
Key genes include AIRE, SH2B3 (LNK), ATF3, IL-10, TGF-beta, SOCS1, SOCS3, and OX40L, among others.
How is interferon-gamma production negatively regulated?
It is regulated at transcriptional, post-transcriptional, and signaling levels by factors such as ATF3, AIRE, RNA-binding proteins, microRNAs, and feedback inhibitors like SOCS proteins.
What diseases are associated with dysregulation of type II interferon negative regulation?
Autoimmune diseases (e.g., APECED), chronic infections, cancer immune evasion, and neuroinflammation are associated with dysregulation.
What is the role of AIRE in negative regulation of type II interferon production?
AIRE is a transcription factor that regulates immune tolerance and can influence cytokine production, including IFN-gamma, through its role in thymic negative selection.
How does SH2B3/LNK affect interferon-gamma?
SH2B3/LNK is an adaptor protein that modulates cytokine signaling; a SNP in SH2B3 is linked to hypertension and renal damage, and it may affect IFN-gamma production.
Can CRISPR be used to study negative regulation of type II interferon production?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of specific genes in this pathway.
What methods are used to measure IFN-gamma production?
ELISA, flow cytometry, RNA-seq, and CRISPR screens are commonly used to measure IFN-gamma production and identify regulators.
What is the difference between type I and type II interferon?
Type I interferons (e.g., IFN-alpha/beta) are primarily antiviral, while type II interferon (IFN-gamma) is a key activator of macrophages and Th1 immunity.
How does post-transcriptional control affect IFN-gamma production?
RNA-binding proteins and microRNAs can destabilize IFN-gamma mRNA or inhibit its translation, providing a rapid way to reduce IFN-gamma production.
Conclusion
GO:0032689, negative regulation of type II interferon production, is a critical biological process that maintains immune homeostasis by preventing excessive IFN-gamma production. Dysregulation of this process contributes to autoimmunity, chronic inflammation, and cancer. The genes and mechanisms involved, including AIRE, SH2B3, ATF3, and post-transcriptional regulators, offer promising targets for therapeutic intervention. CRISPR-based models are indispensable for dissecting these pathways and validating causal relationships. EDITGENE provides comprehensive services to support such research, from knockout and point mutation models to library screening and bioinformatics.
References
- 1. Bez P et al.. 2024. Where AIRE we now? Where AIRE we going?. Curr Opin Allergy Clin Immunol 24(6):448-456 PMID: 39440452
- 2. Alexander MR et al.. 2022. A Single Nucleotide Polymorphism in SH2B3/LNK Promotes Hypertension Development and Renal Damage.. Circ Res 131(9):731-747 PMID: 36169218
- 3. Li J et al.. 2008. Negative regulation of IL-17 production by OX40/OX40L interaction.. Cell Immunol 253(1-2):31-7 PMID: 18501882
- 4. Maeda M et al.. 2017. Induction of IL-17 production from human peripheral blood CD4+ cells by asbestos exposure.. Int J Oncol 50(6):2024-2032 PMID: 28498408
- 5. Panagiotakopoulou V et al.. 2020. Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells.. Nat Commun 11(1):5163 PMID: 33057020
- 6. Platanias LC et al.. 1999. Signaling pathways activated by interferons.. Exp Hematol 27(11):1583-92 PMID: 10560905
- 7. Jung DH et al.. 2015. Involvement of ATF3 in the negative regulation of iNOS expression and NO production in activated macrophages.. Immunol Res 62(1):35-45 PMID: 25752455
- 8. Khabar KS et al.. 2007. Post-transcriptional control of the interferon system.. Biochimie 89(6-7):761-9 PMID: 17408842
